Return to List

Study Summary
No. ID02-230:.......Leukemia; Lymphoma......Susan O'Brien......Leukemia
.
Study Summary Title
Study Summary
Number:		ID02-230
Study Title:PHASE II STUDY OF THE MODIFIED HYPER-CVAD PROGRAM FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
.
Physician New Patient Referral
Name:Susan O'BrienPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:LeukemiaReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-7543
Contact us about clinical trials
.
General Information
Disease Group:Leukemia
Lymphoma		Supported By:none
Phase of Study:Phase IIReturn
Visit:		Induction chemotherapy must be given at MDACC, then every 2-4 courses thereafter during intensive chemotherapy.
Treatment
Agents:		Methotrexate
ARA-C
Rituximab
Cyclophosphamide
Doxorubicin
Vincristine		Home Care:Intensive chemotherapy courses will be prescribed by M.D.Anderson physician or PI. All chemotherapy treatment may be given by local oncologist except for the induction chemotherapy course.
Treatment Loc:both inpatient and outpatient
Estimated
Length of Stay
in Houston:		Four-five days for chemotherapy every 3 weeks; 21-28 days if in the protected environment for induction; 2-5 days if sepsis or other leukemia related event occurs.
Description/
Intervention:		Unavailable
.
Study Objectives / Outcomes
Unavailable
.
Study Status Information
Study Activation / Registration Date:11/13/2002
IRB Review and Approval Date:05/15/2002
Study Type:Therapeutic
Recruitment Status:Open
Projected Accrual:145
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:Newly diagnosed, previously untreated ALL or lymphoblastic lymphoma, or having achieved CR with one course of induction chemotherapy.

Failure to one induction course of chemotherapy are eligible.

All ages are eligible.

Zubrod performance status of 3 or better.

Adequate liver function (bilirubin =/<3.0 mg/dl unless due to tumor) & renal function (creatinine =/<3.0 mg/dl, unless due to tumor).

Adequate cardiac function as assessed by history and physical examination.

No active co-existing malignancy with life expectancy less than 12 months due to that malignancy.
.
Links
Registration Number: NCT00671658
Study Information on Clinical Trials Registry (clinicaltrials.gov)
Other Links:
.
Results

Return to Clinical Trials at M.D. Anderson Cancer Center